アポリポプロテインMの減少と,ヒトの心不全の全スペクトルの有害な結果
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
PubMedで要約を見る
まとめ
この要約は機械生成です。アポリポプロテインM (apo M) の値低下は,心不全患者での結果の悪化と関連しています. これは,アポM/スフィンゴシン-1-ホスファート (S1P) 経路が治療目標である可能性を示唆する.
科学分野
- 心臓病科
- 生物化学
- 分子生物学
背景
- アポリポプロテインM (Apo M) は,高密度リポプロテイン (HDL) とスフィンゴシン-1- リン酸 (S1P) の相互作用を促進します.
- Apo Mは,前臨床モデルにおいて,抗炎症性および心臓保護性を示した.
研究 の 目的
- 循環中のApo M濃度と心不全患者の臨床結果との関連を調査する.
- 心不全におけるApo M,HDL関連S1P,および生物学的経路の関係を探求する.
主な方法
- アポMと総S1P値は,ELISAと液体染色体質スペクトロメトリーを用いて心不全患者で測定された.
- Apo Mとアウトカムとの関連性は,複数の独立したコホートで確認された.
- プロテオミック分析 (SomaScan) によって,心不全におけるApo Mに関連した生物学的経路が特定されました.
主要な成果
- 心不全の患者では,Apo Mの低濃度が死亡リスクや主要な心血管疾患の有害事象の増加と独立して関連していた.
- APO Mレベルは,HDL粒子のS1P含有量と強く相関していた.
- 主な経路は炎症と凝固であり,逆の関係が見られた.
結論
- 循環中のApo Mの減少は,心不全の全スペクトルの患者における有害な結果の独立した予測因子です.
- Apo M/S1P軸は,心不全の潜在的治療目標としてさらなる調査を必要としています.
関連する概念動画
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...